A article reported by the Natural News had mentioned that Nabi Biopharmaceuticals together with GlaxoSmithKline (GSK) had partnered to experiment an anti-smoking vaccine. However, this experiment actually failed badly. The objective of the experiment was to trigger the antibodies production that will prevent nicotine to reach the brain when people smoke.
This yearlong experiment involved 1000 people who were given either the NicVAX or placebo shot. Yet, the results of people quitting smoking from both groups in Phrase III trials were the same. So what this meant was that the drug simply had no visible impact in helping people to quit smoking! Also to make things worse, according to the Nabi's company website, Nabi had openly received a grant of $4.1million from US National Drug Institute on Drug Abuse (NIDA) to fund the project in 2005! What a waste of taxpayer dollars!
To read full article, click here.
Leading biopharmaceutical companies will be sharing their ideas and concerns at the conference Pharma Trials World Asia in Singapore at 6th annual BioPharma Asia 2013. Contact Rebecca Koh at +65 6322 2725 or firstname.lastname@example.org to find out more about it! Visit our website here.